NivolumabTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Sponsor:

National Cancer Institute (NCI)

Code:

NCT03816345

Conditions

Autoimmune Disease

Crohn Disease

Dermatomyositis

Hematopoietic and Lymphoid Cell Neoplasm

Inflammatory Bowel Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Cabozantinib

Fluoropyrimidine

Ipilimumab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-07-31.